We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-22.97%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
–
Cap. Flow
+$66.6M
Cap. Flow %
114.6%
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$66.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.51B
$58.1M 100%
+4,429,788
New +$66.6M

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q4 2016 Portfolio in Review

Q4 2016 is the first quarter with a 13F filing on record for Atlas Venture Associates IX, which disclosed 1 position worth $58.1M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Intellia Therapeutics: 4,429,788 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Atlas Venture Associates IX's largest Q4 2016 buy was Intellia Therapeutics: 4,429,788 shares worth $58.1M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $58.1M portfolio in Q4 2016.
  • Atlas Venture Associates IX disclosed 1 position in Q4 2016, its first 13F filing on record.

Based on Atlas Venture Associates IX's 13F filing for Q4 2016, filed 10 Feb 2017.